This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia

This study has been completed.
Information provided by:
Eisai Inc. Identifier:
First received: September 13, 2005
Last updated: May 8, 2013
Last verified: November 2005
A randomised, double-blind, 3-arm parallel group study comparing Aricept® with placebo.

Condition Intervention Phase
Dementia With Parkinson's Disease Drug: ARICEPT Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Eisai Inc.:

Primary Outcome Measures:
  • PD patients with dementia will be screened up to 4 weeks prior to initiating dose administration. Baseline measurement on efficacy measures will be conducted at baseline, after which the first dose of study medication will be administered.

Study Start Date: August 2002
Estimated Study Completion Date: July 2005

Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All

Patients with an established diagnosis of PD and dementia, who fulfill all of the inclusion criteria and none of the exclusion criteria listed below, will be eligible for enrolment into this study.

Best efforts must be made on clinical grounds to exclude patients with DLB and AD. The key inclusion criteria in this respect is the onset of dementia documented to have occurred at least 1 year after the diagnosis of PD.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00165815

Allgemeines Krankenhaus Barmbeck
Hamburg, Hambug, Germany
Parkinson Klinik Wolfach
Wolfach, Germany
Belfast City Hospital
Belfast, Ireland
Unit 20 Black Poo Technology Centerl
Blackpool, Ireland
Sponsors and Collaborators
Eisai Limited
Study Director: Jina Schwartz Eisai Limited
  More Information Identifier: NCT00165815     History of Changes
Other Study ID Numbers: E2020-E044-316
Study First Received: September 13, 2005
Last Updated: May 8, 2013

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Nootropic Agents processed this record on September 21, 2017